Mga Batayang Estadistika
| CIK | 891288 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2014 |
As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
S-8 POS 1 d777358ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-175972 Registration No. 333-151395 Registration No. 333-134878 Registration No. 333-116624 Registration No. 333-105694 Registration No. 333-105693 Registration No. 333-46990 Registration No. 333-30558 Registration No. 333-81243 Registration No. 33-91254 Registration No. |
|
| August 14, 2014 |
POS AM 1 d772549dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-25661 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
POS AM 1 d777476dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-61866 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
8-K 1 d772821d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) California 001-14758 33-0476164 (State or Other Jur |
|
| August 14, 2014 |
S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
POS AM 1 d777470dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-17501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
POS AM 1 d777352dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 33-80645 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
POS AM 1 d772433dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-23085 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
MALLINCKRODT AND QUESTCOR SHAREHOLDERS APPROVE MALLINCKRODT’S ACQUISITION OF QUESTCOR EX-99.1 2 d772821dex991.htm EX-99.1 Exhibit 99.1 MALLINCKRODT AND QUESTCOR SHAREHOLDERS APPROVE MALLINCKRODT’S ACQUISITION OF QUESTCOR DUBLIN, IRELAND and ANAHEIM, Calif., Aug. 14, 2014 — Mallinckrodt plc (NYSE: MNK) and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today jointly announced that all proposals necessary for Mallinckrodt’s acquisition of Questcor were approved by Mallinckrodt’s and Q |
|
| August 14, 2014 |
As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
POS AM 1 d772398dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-102988 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Californi |
|
| August 14, 2014 |
S-8 POS 1 d777358ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-175972 Registration No. 333-151395 Registration No. 333-134878 Registration No. 333-116624 Registration No. 333-105694 Registration No. 333-105693 Registration No. 333-46990 Registration No. 333-30558 Registration No. 333-81243 Registration No. 33-91254 Registration No. |
|
| August 14, 2014 |
POS AM 1 d777455dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 33-97970 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
POS AM 1 d777355dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-107755 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Californi |
|
| August 14, 2014 |
POS AM 1 d772386dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-114166 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Californi |
|
| August 14, 2014 |
POS AM 1 d777491dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-32159 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
POS AM 1 d772501dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-85160 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
S-8 POS 1 d777358ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-175972 Registration No. 333-151395 Registration No. 333-134878 Registration No. 333-116624 Registration No. 333-105694 Registration No. 333-105693 Registration No. 333-46990 Registration No. 333-30558 Registration No. 333-81243 Registration No. 33-91254 Registration No. |
|
| August 14, 2014 |
As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. |
|
| August 14, 2014 |
POS AM 1 d777482dposam.htm POS AM As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 33-72770 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QUESTCOR PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) California |
|
| August 14, 2014 |
S-8 POS 1 d777358ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-175972 Registration No. 333-151395 Registration No. 333-134878 Registration No. 333-116624 Registration No. 333-105694 Registration No. 333-105693 Registration No. 333-46990 Registration No. 333-30558 Registration No. 333-81243 Registration No. 33-91254 Registration No. |
|
| August 14, 2014 |
S-8 POS 1 d777358ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on August 14, 2014 Registration No. 333-175972 Registration No. 333-151395 Registration No. 333-134878 Registration No. 333-116624 Registration No. 333-105694 Registration No. 333-105693 Registration No. 333-46990 Registration No. 333-30558 Registration No. 333-81243 Registration No. 33-91254 Registration No. |
|
| August 11, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - 425 425 1 d774172d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Form S-4 File No.: 333-196054 HOME ABOUT MALLINCKRODT ABOUT QUESTCOR THE MERGER Q&A ABOUT MALLINCKRODT PHARMACEUTICALS Today’s Mallinckrodt Pharmaceuticals combines m |
|
| August 11, 2014 |
DEFA14A 1 d774491ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| August 11, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - 425 425 1 d774461d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Form S-4 File No.: 333-196054 The following new questions and answers were posted to http://www.mallinckrodt.com/mnk-qcor/mergerinfo/qa/ Questcor Employee Integration |
|
| August 11, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - FORM 425 425 1 d774468d425.htm FORM 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Form S-4 File No.: 333-196054 August 11, 2014 Dear Mallinckrodt Colleagues: This week, special meetings will be held where the respective shareholders of Mallinc |
|
| August 11, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - 425 425 1 d774477d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Form S-4 File No.: 333-196054 Cautionary Statement Regarding Forward-Looking Statements Statements in this document that are not strictly historical, including statem |
|
| August 7, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - 425 425 1 d770539d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Form S-4 File No.: 333-196054 MNK – Q3 2014 Mallinckrodt plc Earnings Call August 7, 2014 / 12:30PM GMT Mark Trudeau - Mallinckrodt plc - President and CEO On the acq |
|
| August 5, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - 425 425 1 d767670d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Form S-4 File No.: 333-196054 IMPORTANT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS PLEASE VOTE TODAY! August 5, 2014 Dear Fellow Shareholder: According to our late |
|
| July 30, 2014 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION NOTE PURCHASE AGREEMENT Dated as of July 28, 2014 by and among MALLINCKRODT SECURITIZATION S.À R.L., as Issuer, THE PERSONS FROM TIME TO TIME PARTY HERETO, as Purchasers, PNC BANK, NATIONAL ASSOCIATION, as Administrative Agent, and MALLINCKRODT LLC, as initial Servicer Variable Funding Asset Backed Notes TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 SECTION |
|
| July 30, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - FORM 8-K 425 1 d765420d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 29, 2014 (July 28, 2014) Mallinckrodt public limited company (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (St |
|
| July 30, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 30, 2014 Mallinckrodt public limited company (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation or |
|
| July 30, 2014 |
QCOR / 425 - Merger Prospectus - 8-K 425 1 d765179d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2014 Date of Report (Date of earliest event reported) QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of |
|
| July 30, 2014 |
8-K 1 d765179d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2014 Date of Report (Date of earliest event reported) QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of |
|
| July 30, 2014 |
EX-10.4 Exhibit 10.4 EXECUTION COPY PERFORMANCE GUARANTY This PERFORMANCE GUARANTY (as amended, supplemented or otherwise modified from time to time, this “Performance Guaranty”), dated as of July 28, 2014, is made by MALLINCKRODT INTERNATIONAL FINANCE S.A., a public limited liability company (société anonyme) organized under the laws of the Grand Duchy of Luxembourg having its registered office a |
|
| July 30, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 29, 2014 Mallinckrodt public limited company (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisdiction of incorporation or |
|
| July 30, 2014 |
EX-10.2 Exhibit 10.2 EXECUTION COPY PURCHASE AND SALE AGREEMENT Dated as of July 28, 2014 among VARIOUS ENTITIES LISTED ON SCHEDULE I HERETO, as Originators, MALLINCKRODT LLC, as initial Servicer, and MALLINCKRODT SECURITIZATION S.À R.L., as Buyer CONTENTS Clause Subject Matter Page ARTICLE I AGREEMENT TO PURCHASE AND SELL 2 SECTION 1.1 Agreement To Purchase and Sell 2 SECTION 1.2 Timing of Purcha |
|
| July 30, 2014 |
EX-10.3 4 d765420dex103.htm EX-10.3 Exhibit 10.3 SALE AGREEMENT This Sale Agreement, dated as of July 28, 2014 (this “Agreement”), is between LIEBEL-FLARSHEIM COMPANY LLC, a Delaware limited liability company (the “Seller”), and MALLINCKRODT LLC, a Delaware limited liability company (the “Buyer”). W I T N E S S E T H : WHEREAS, the Seller is a direct wholly-owned subsidiary of the Buyer; WHEREAS, |
|
| July 28, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - 425 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. |
|
| July 25, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) |
|
| July 25, 2014 |
EX-99.1 2 d762553dex991.htm EX-99.1 Exhibit 99.1 Questcor Reports Record Second Quarter Financial Results Net Sales $279 Million; Increase of 42% over Prior Year Non-GAAP Results GAAP EPS of $1.54, Non-GAAP EPS of $1.85 up 37% Year-Over-Year $99 Million of Operating Cash Flow Record 8,850 Acthar Vials Shipped in Quarter, up 26% over Prior Year Launched Commercial Effort in Lupus Expanding Pulmonol |
|
| July 25, 2014 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER: 0 |
|
| July 25, 2014 |
Exhibit 10.6 AMENDMENT This AMENDMENT (the “Amendment”), dated as of May 19, 2014, is made and entered into by and between Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), and David Medeiros (the “Executive”). RECITALS WHEREAS, the Company, Mallinckrodt plc, an Irish public limited company and Quincy Merger Sub, Inc. a Delaware corporation (the “Merger Sub”), have entered |
|
| July 25, 2014 |
AMENDMENT TO QUESTCOR PHARMACEUTICALS, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE AWARD PLAN Exhibit 10.1 AMENDMENT TO QUESTCOR PHARMACEUTICALS, INC. AMENDED AND RESTATED 2006 EQUITY INCENTIVE AWARD PLAN This Amendment (“Amendment”) to the Questcor Pharmaceuticals, Inc. Amended and Restated 2006 Equity Incentive Award Plan (the “Plan”), is adopted by the Board of Directors (the “Board”) of Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), effective as of April 5, 2 |
|
| July 25, 2014 |
Exhibit 10.4 AMENDMENT This AMENDMENT (the “Amendment”), dated as of May 28, 2014, is made and entered into by and between Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), and Don M. Bailey (the “Executive”). RECITALS WHEREAS, the Company, Mallinckrodt plc, an Irish public limited company and Quincy Merger Sub, Inc. a Delaware corporation (the “Merger Sub”), have entered i |
|
| July 25, 2014 |
Exhibit 10.7 AMENDMENT This AMENDMENT (the “Amendment”), dated as of May 23, 2014, is made and entered into by and between Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), and David Young (the “Executive”). RECITALS WHEREAS, the Company, Mallinckrodt plc, an Irish public limited company and Quincy Merger Sub, Inc. a Delaware corporation (the “Merger Sub”), have entered int |
|
| July 25, 2014 |
Exhibit 10.5 AMENDMENT This AMENDMENT (the “Amendment”), dated as of May 16, 2014, is made and entered into by and between Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), and Stephen Cartt (the “Executive”). RECITALS WHEREAS, the Company, Mallinckrodt plc, an Irish public limited company and Quincy Merger Sub, Inc. a Delaware corporation (the “Merger Sub”), have entered i |
|
| July 25, 2014 |
Exhibit 10.3 AMENDMENT This AMENDMENT (the “Amendment”), dated as of May 13, 2014, is made and entered into by and between Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), and Rajesh Asarpota (the “Executive”). RECITALS WHEREAS, the Company, Mallinckrodt plc, an Irish public limited company and Quincy Merger Sub, Inc. a Delaware corporation (the “Merger Sub”), have entered |
|
| July 25, 2014 |
Exhibit 10.2 AMENDMENT This AMENDMENT (the “Amendment”), dated as of April 6, 2014, is made and entered into by and between Questcor Pharmaceuticals, Inc., a California corporation (the “Company”), and Michael Mulroy (the “Executive”). RECITALS WHEREAS, the Company, Mallinckrodt plc, an Irish public limited company and Quincy Merger Sub, Inc. a Delaware corporation (the “Merger Sub”), have entered |
|
| July 14, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - FORM 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. |
|
| July 14, 2014 |
DEFA14A 1 d757780ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as |
|
| July 14, 2014 |
DEFM14A 1 d708020ddefm14a.htm DEFM14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Co |
|
| July 14, 2014 |
MNK / Mallinckrodt PLC 425 - Merger Prospectus - 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. |
|
| July 10, 2014 |
EX-99.1 2 d755101dex991.htm EX-99.1 Exhibit 99.1 Item 1. Business Business Overview We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. We also supply specialty contract manufacturing services to the global pharmaceutical and biotechnology industry through our wholly-owned subsidiary, BioVectra Inc. We have |
|
| July 10, 2014 |
8-K 1 d755101d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| July 10, 2014 |
QCOR / 425 - Merger Prospectus - FORM 8-K 425 1 d755101d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| July 10, 2014 |
EX-99.1 2 d755101dex991.htm EX-99.1 Exhibit 99.1 Item 1. Business Business Overview We are a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. We also supply specialty contract manufacturing services to the global pharmaceutical and biotechnology industry through our wholly-owned subsidiary, BioVectra Inc. We have |
|
| July 3, 2014 |
CORRESP Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 July 3, 2014 VIA EDGAR Scott Wuenschell Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2014 Filed February 26, 2014 Response dated June 24, 2014 File No. 001 |
|
| June 24, 2014 |
CORRESP 1 filename1.htm Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 June 24, 2014 VIA EDGAR Scott Wuenschell Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 26, 2014 File No. 001-14758 Dear |
|
| June 16, 2014 |
CORRESP 1 filename1.htm Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 June 16, 2014 VIA EDGAR Mr. Joel Parker, Accounting Branch Chief Mr. Jeffrey P. Riedler, Assistant Director Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended |
|
| June 9, 2014 |
CORRESP 1 filename1.htm Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 June 9, 2014 VIA EDGAR CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO C.F.R. §200.83 Mr. Joel Parker Accounting Branch Chief Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fi |
|
| June 4, 2014 |
Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 June 4, 2014 VIA EDGAR Mr. Scott Wuenschell Staff Accountant Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 26, 2014 File No. 001-14758 Dear Mr. |
|
| May 20, 2014 |
CORRESP 1 filename1.htm Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 May 20, 2014 VIA EDGAR Mr. Scott Wuenschell Staff Accountant Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 26, 2014 File |
|
| May 16, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) |
|
| May 12, 2014 |
425 1 d723996d425.htm FORM 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No.: 001-14758 MALLINCKRODT PHARMACEUTICALS AND QUESTCOR PHARMACEUTICALS ANNOUNCE EARLY TERMINATION OF HSR ACT WAITING PERIOD DUBLIN, IRELAND and |
|
| May 9, 2014 |
425 1 d725337d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No.: 001-14758 THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us 1 © 2014 Thomson Reuters. All rights reserved. Republication or redist |
|
| May 9, 2014 |
Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. |
|
| May 6, 2014 |
EX-99.1 2 d723174dex991.htm EX-99.1 Exhibit 99.1 Questcor Reports First Quarter Financial Results - Net Sales $227 Million; Increase 68% Year-over-Year - - GAAP EPS of $1.20, Non-GAAP EPS of $1.40 up 84% - - $106M of Operating Cash Flow - - Rheumatology Largest Growth Contributor - - Mallinckrodt / Questcor Joint Merger Proxy Expected to be Filed in Mid-May - ANAHEIM, Calif., April 28, 2014 — Ques |
|
| May 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d723174d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdic |
|
| May 2, 2014 |
QCOR / / Adage Capital Partners GP LLC - QUESTCOR PHARMACEUTICALS, INC. Passive Investment SC 13G 1 p14-1178sc13g.htm QUESTCOR PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* QUESTCOR PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 74835Y101 (CUSIP Number) April 24, 2014 (Date of Event Which Requires Filing of This Statement) Check the |
|
| April 30, 2014 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 to Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-14758 Questcor Ph |
|
| April 29, 2014 |
10-Q 1 qcor-2014331x10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE TRANSITION PERIOD |
|
| April 24, 2014 |
AMENDMENT TO THE RIGHTS AGREEMENT EX-4.1 2 d713679dex41.htm EX-4.1 Exhibit 4.1 AMENDMENT TO THE RIGHTS AGREEMENT This AMENDMENT TO THE RIGHTS AGREEMENT (this “Amendment”), executed as a Deed Poll, is made and entered into as of April 23, 2014, between Mallinckrodt plc, an Irish public limited company (the “Company”), and Computershare Trust Company, N.A., as rights agent (the “Rights Agent”). All capitalized terms used in this Ame |
|
| April 24, 2014 |
EX-10.1 3 d713679dex101.htm EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT (“Agreement”), executed as a Deed, is made and entered into as of April 23, 2014, by and among Mallinckrodt plc, an Irish public limited company (the “Company”) and Paulson & Co. Inc. on behalf of itself and of all funds and accounts managed by Paulson & Co. Inc. or any of its affiliates, each of which shall |
|
| April 24, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 24, 2014 (April 23, 2014) Mallinckrodt public limited company (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State or other jurisd |
|
| April 8, 2014 |
425 Filed by Questcor Pharmaceuticals, Inc. Commission File No. 001-14758 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No. 001-14758 THOMSON REUTERS STREETEVENTS EDITED TRANSCRIPT MNK - Mallinckrodt Plc Conference Call to discuss Acquisition of |
|
| April 7, 2014 |
425 1 d707513d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No.: 001-14758 Transcript Mallinckrodt Employees Video Message Script April 7, 2014 Participant: Mark Trudeau, President and CEO of Mallinckrodt plc H |
|
| April 7, 2014 |
EX-2.1 2 d708240dex21.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among MALLINCKRODT PLC, QUINCY MERGER SUB, INC. and QUESTCOR PHARMACEUTICALS, INC. dated as of April 5, 2014 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Governing Documents 3 Section 1.5 Officers and Directors of the Surviving Co |
|
| April 7, 2014 |
Form 425 Mallinckrodt-Questcor Transaction Creates Diversified, High-Growth Specialty Pharmaceutical Company April 7, 2014 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. |
|
| April 7, 2014 |
425 1 d708095d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No.: 001-14758 MALLINCKRODT/QUESTCOR PHARMACEUTICALS Managers’ Tool Kit FAQ – 4-7-14 TRANSACTION – STRATEGIC RATIONALE 1. What are the key highlights |
|
| April 7, 2014 |
EX-2.1 2 d708301dex21.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among MALLINCKRODT PLC, QUINCY MERGER SUB, INC. and QUESTCOR PHARMACEUTICALS, INC. dated as of April 5, 2014 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Governing Documents 3 Section 1.5 Officers and Directors of the Surviving Co |
|
| April 7, 2014 |
Filed by Questcor Pharmaceuticals, Inc. Commission File No. 001-14758 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No. 001-14758 Transcript Questcor Employees Video Message Script April 7, 2014 Participants: Don Bailey, President and CEO of Que |
|
| April 7, 2014 |
EX-99.1 3 d708301dex991.htm EX-99.1 Exhibit 99.1 MALLINCKRODT PHARMACEUTICALS AND QUESTCOR PHARMACEUTICALS ENTER INTO DEFINITIVE MERGER AGREEMENT UNDER WHICH MALLINCKRODT WILL ACQUIRE QUESTCOR FOR APPROXIMATELY $5.6 BILLION, CREATING A DIVERSIFIED, HIGH-GROWTH SPECIALTY PHARMACEUTICALS COMPANY —Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Co |
|
| April 7, 2014 |
425 1 d708301d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 7, 2014 (April 5, 2014) Mallinckrodt public limited company (Exact name of registrant as specified in its charter) Ireland 001-35803 98-1088325 (State o |
|
| April 7, 2014 |
Filed by Questcor Pharmaceuticals, Inc. Commission File No. 001-14758 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No. 001-14758 April 7, 2014 Dear Questcor Employees: I am writing to share some important and exciting news about our company. To |
|
| April 7, 2014 |
425 1 d708240d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction o |
|
| April 7, 2014 |
425 1 d707519d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No.: 001-14758 Transcript Questcor Employees Video Message Script April 7, 2014 Participants: Don Bailey, President and CEO of Questcor Pharmaceutical |
|
| April 7, 2014 |
EX-99.1 3 d708240dex991.htm EX-99.1 Exhibit 99.1 MALLINCKRODT PHARMACEUTICALS AND QUESTCOR PHARMACEUTICALS ENTER INTO DEFINITIVE MERGER AGREEMENT UNDER WHICH MALLINCKRODT WILL ACQUIRE QUESTCOR FOR APPROXIMATELY $5.6 BILLION, CREATING A DIVERSIFIED, HIGH-GROWTH SPECIALTY PHARMACEUTICALS COMPANY —Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Co |
|
| April 7, 2014 |
EX-99.1 3 d708240dex991.htm EX-99.1 Exhibit 99.1 MALLINCKRODT PHARMACEUTICALS AND QUESTCOR PHARMACEUTICALS ENTER INTO DEFINITIVE MERGER AGREEMENT UNDER WHICH MALLINCKRODT WILL ACQUIRE QUESTCOR FOR APPROXIMATELY $5.6 BILLION, CREATING A DIVERSIFIED, HIGH-GROWTH SPECIALTY PHARMACEUTICALS COMPANY —Questcor Shareholders Receive $30.00 in Cash and 0.897 Mallinckrodt Shares for Each Share of Questcor Co |
|
| April 7, 2014 |
425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. |
|
| April 7, 2014 |
425 1 d708089d425.htm 425 Filed by Mallinckrodt plc Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934 Subject Company: Questcor Pharmaceuticals, Inc. Commission File No.: 001-14758 Letter of Mark Trudeau, Mallinckrodt’s President and Chief Executive Officer, to Mallinckrodt Employees This marks an incredibly exciti |
|
| April 7, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Com |
|
| April 7, 2014 |
EX-2.1 2 d708240dex21.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among MALLINCKRODT PLC, QUINCY MERGER SUB, INC. and QUESTCOR PHARMACEUTICALS, INC. dated as of April 5, 2014 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Governing Documents 3 Section 1.5 Officers and Directors of the Surviving Co |
|
| March 3, 2014 |
EX-99.1 Exhibit 99.1 Questcor Reports Fourth Quarter and Full Year 2013 Financial Results - Fourth Quarter Net Sales $243 Million; Increase 51% Year-over-Year - - Fourth Quarter GAAP EPS of $1.44, Non-GAAP EPS of $1.67 up 53% - - Full Year 2013 Net Sales $799 Million; Increase 57% Year-over-Year - - Full Year GAAP EPS of $4.76, Non-GAAP EPS of $5.48 up 65% - - Rheumatology Largest Growth Contribut |
|
| March 3, 2014 |
EX-99.2 3 d687381dex992.htm EX-99.2 Exhibit 99.2 Operator: Good day, ladies and gentlemen. Welcome to the Questcor Pharmaceutical’s Fourth Quarter and Full Year 2013 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this conferenc |
|
| March 3, 2014 |
8-K 1 d685647d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| March 3, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d687381d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| March 3, 2014 |
EX-99.3 4 d687381dex993.htm EX-99.3 Exhibit 99.3 NASDAQ: QCOR Fourth Quarter and Full Year 2013 Conference Call Conference Call Logistics Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 55826448 2 This presentat |
|
| February 26, 2014 |
Questcor Pharmaceuticals, Inc. List of Subsidiaries EXHIBIT 21.1 Questcor Pharmaceuticals, Inc. List of Subsidiaries 1. BioVectra, Inc., a corporation governed by the laws of Prince Edward Island, Canada. 2. Questcor International Limited, an Irish private limited company. 3. Questcor Operations Limited, an Irish private limited company. |
|
| February 26, 2014 |
10-K 1 questcor-10k2013.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year ended December 31, 2013 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-14758 Questcor |
|
| February 14, 2014 |
QCOR / / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 12, 2014 |
EX-99.1 3 d677744dex991.htm EX-99.1 Exhibit 99.1 February 5, 2014 Questcor Pharmaceuticals Expands Senior Management Team ANAHEIM, Calif., Feb. 5, 2014 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the appointment of Rajesh (Raj) Asarpota as the Company’s new Chief Financial Officer, effective February 17, 2014. Michael H. Mulroy, the Company’s current CFO, will beco |
|
| February 12, 2014 |
QCOR / / VANGUARD GROUP INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2 )* Name of issuer: Questcor Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 74835Y101 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 12, 2014 |
EX-10.1 2 d677744dex101.htm EX-10.1 Exhibit 10.1 January 13, 2014 Rajesh (Raj) Asarpota 7056 Heron Circle Carlsbad, CA 92011 Re: Offer of Employment Dear Rajesh: Questcor is pleased to extend an offer of employment to you for the position of Senior Vice President, Chief Financial Officer and Principal Accounting Officer with a hire date of February 17, 2014. You will report to Don Bailey, Presiden |
|
| February 12, 2014 |
8-K 1 d677744d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisd |
|
| February 3, 2014 |
QCOR / / BRADSHER NEAL C Activist Investment SC 13D/A 1 d144952413d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) Questcor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74835Y101 (CUSIP Number) Neal C. Bradsher c/o Broadwood Capital, Inc. 724 Fifth Avenue, 9th Floor New York, New York 10019 (Name, Address an |
|
| January 23, 2014 |
8-K 1 d664241d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisd |
|
| January 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Comm |
|
| January 13, 2014 |
EX-99.1 2 d658915dex991.htm EX-99.1 NASDAQ: QCOR J.P. Morgan Healthcare Conference January 16, 2014 Exhibit 99.1 Safe Harbor Statement 2 Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future finan |
|
| January 13, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2014 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 11, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d640390d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juris |
|
| December 11, 2013 |
8-K 1 d639969d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| December 11, 2013 |
EX-99.1 Exhibit 99.1 NASDAQ: QCOR OPPENHEIMER Healthcare Conference December 11, 2013 Exhibit 99.1 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance |
|
| November 15, 2013 |
QCOR / / BROADWOOD PARTNERS, L.P. Activist Investment SC 13D/A 1 d143048913d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) Questcor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74835Y101 (CUSIP Number) Neal C. Bradsher c/o Broadwood Capital, Inc. 724 Fifth Avenue, 9th Floor New York, New York 10019 (Name, Address an |
|
| November 14, 2013 |
Questcor Adds G. Kelly Martin to Board of Directors EX-99.1 2 d627323dex991.htm EX-99.1 Exhibit 99.1 Questcor Adds G. Kelly Martin to Board of Directors ANAHEIM, CA – November 12, 2013 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the addition of G. Kelly Martin, President and Chief Executive Officer of Elan Corporation, plc, to Questcor’s Board of Directors, bringing the number of directors to eight, seven of whom are independent |
|
| November 14, 2013 |
8-K 1 d627323d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisd |
|
| November 4, 2013 |
EX-99.3 1 1 Third Quarter 2013 Conference Call Third Quarter 2013 Conference Call NASDAQ: QCOR NASDAQ: QCOR Exhibit 99.3 2 • Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm • Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 76004546 • Today’s webcast, accompan |
|
| November 4, 2013 |
EX-99.1 Exhibit 99.1 Questcor Reports Third Quarter Financial Results - Net Sales and EPS Increase Over 65% Compared to Prior Year - - Vial Shipments up 45% Over Prior Year - - Record MS Prescriptions; Rheumatology Largest Growth Contributor - ANAHEIM, Calif., October 29, 2013 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the third quarter and nine months end |
|
| November 4, 2013 |
EX-99.2 Exhibit 99.2 Operator: Good day, ladies and gentlemen. Welcome to the Questcor Pharmaceutical’s Q3 2013 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to introduc |
|
| November 4, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) ( |
|
| October 30, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMB |
|
| October 7, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 7, 2013 |
EX-99.1 Exhibit 99.1 Questcor continues its evolution from a small, struggling specialty pharmaceutical company to an emerging leader in the development and commercialization of melanocortin peptides targeting the regulation of immune system and inflammatory processes. The foundation for our exciting transformation is Acthar, our flagship product approved by the FDA for a number of serious, diffic |
|
| August 6, 2013 |
EX-99.1 2 d580909dex991.htm EX-99.1 1 August 2013 NASDAQ: QCOR NASDAQ: QCOR Exhibit 99.1 1 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In s |
|
| August 6, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d580909d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdic |
|
| August 6, 2013 |
EX-99.3 Exhibit 99.3 NASDAQ: QCOR Second Quarter 2013 Conference Call Conference Call Logistics Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm Telephone replay is available by dialing: U.S.: (855) 859-2056. International: (404) 537-3406. Passcode: 16591264 2 Safe Harbor Statement Note: Except for the historical informat |
|
| August 6, 2013 |
EX-99.2 3 d580892dex992.htm EX-99.2 Operator Good day, ladies and gentlemen, and welcome to the Questcor Pharmaceuticals second quarter of 2013 earnings conference call. At this time, all participates are in a listen-only mode. Later, we’ll conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions). As a reminder, this conference is being recorded. I |
|
| August 6, 2013 |
EX-99.1 Exhibit 99.1 Questcor Reports Second Quarter Financial Results - Net Sales and EPS Increase Significantly Over Prior Year - - Vial Shipments up 50% Over Prior Year - - Total Shipped Rxs up 35% YOY; Rheumatology Rxs Largest Growth Contributor - ANAHEIM, Calif., July 30, 2013 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the second quarter and six month |
|
| August 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) |
|
| August 5, 2013 |
8-K 1 d580361d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| July 12, 2013 |
Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis EX-99.1 2 d567566dex991.htm EX-99.1 Exhibit 99.1 Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis ANAHEIM, CA – July 11, 2013 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced its intent to initiate a pilot commercialization effort for H.P. Acthar® Gel (repository corticotropin injection) for the treatment of respiratory manifestations of |
|
| July 12, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d567566d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| June 11, 2013 |
EX-99.1 2 d552318dex991.htm EX-99.1 EXHIBIT 99.1 Questcor Pharmaceuticals Acquires Rights to Synacthen® – Expands Questcor’s Presence in Inflammatory and Autoimmune Disorders – – Provides Foundation for Next Generation Melanocortin Receptor Agonist Therapeutics – – Initiates Global Footprint, Diversifies Business, Enhances Long-term Growth Prospects – ANAHEIM, CA, June 11, 2013 — Questcor Pharmace |
|
| June 11, 2013 |
8-K 1 d551969d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| June 11, 2013 |
Questcor Adds Angus C. Russell to Board of Directors EX-99.1 EXHIBIT 99.1 Questcor Adds Angus C. Russell to Board of Directors ANAHEIM, CA – June 10, 2013 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the addition of Angus C. Russell, recently-retired Chief Executive Officer of Shire plc, to Questcor’s Board of Directors. Shire is a global specialty biopharmaceutical company whose 2012 revenues exceeded $4.6 billion. During Mr. Rus |
|
| June 11, 2013 |
8-K 1 d552318d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| May 31, 2013 |
Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 May 31, 2013 VIA EDGAR CORRESPONDENCE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2012 Filed Febr |
|
| May 30, 2013 |
8-K 1 d546949d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| May 14, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d537935d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| May 14, 2013 |
EX-99.1 2 d537935dex991.htm EX-99.1 1 1 May 2013 NASDAQ: QCOR NASDAQ: QCOR Bank of America Merrill Lynch Healthcare Conference Don Bailey Chief Executive Officer Exhibit 99.1 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995 |
|
| May 6, 2013 |
EX-99.2 3 d532666dex992.htm EX-99.2 Exhibit 99.2 MANAGEMENT DISCUSSION SECTION Operator: Good day, ladies and gentlemen, and welcome to the Questcor Pharmaceuticals, Incorporated First Quarter 2013 Earnings Conference. [Operator Instructions] Later, we will conduct a question-and-answer session, and instructions will be given at that time. [Operator Instructions] As a reminder, this call may be re |
|
| May 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d532666d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdic |
|
| May 6, 2013 |
EX-99.1 2 d532666dex991.htm EX-99.1 Exhibit 99.1 April 30, 2013 Questcor Reports First Quarter Financial Results - Net Sales Increase 41% Year Over Year; Down Sequentially - - April Vial Shipments Rebound Significantly Establishing a New Monthly Record - - Prescription Levels in Rheumatology Increasing - - Phase 2 Clinical Trial of Acthar in ALS to Start under FDA Accepted IND - ANAHEIM, Calif., A |
|
| May 6, 2013 |
EX-99.3 4 d532666dex993.htm EX-99.3 Exhibit 99.3 NASDAQ: QCOR First Quarter 2013 Conference Call Conference Call Logistics Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our futu |
|
| April 15, 2013 |
DEF 14A 1 def14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¬ Preliminary Proxy Statement ¬ Confidential, for Use of the Commission |
|
| April 12, 2013 |
DEFR14A 1 def14a.htm DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¬ Preliminary Proxy Statement ¬ Confidential, for Use of the Commission Only (as permitted |
|
| April 12, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS DEF 14A 1 schedule14anoticeofavailab.htm DEFINITIVE ADDITIONAL MATERIALS SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 3, 2013 |
EX-99.1 4 exhibit991.htm EXHIBIT Exhibit 99.1 November 2, 2012, except as to Note 17 which is as of February 25, 2013 Independent Auditor’s Report To the Shareholders of BioVectra Inc. We have audited the accompanying consolidated financial statements of BioVectra Inc., which comprise the balance sheets as at August 31, 2012, August 31, 2011 and September 1, 2010, and the consolidated statements o |
|
| April 3, 2013 |
EX-99.2 5 exhibit992.htm EXHIBIT Exhibit 99.2 BioVectra Inc. Consolidated Interim Balance Sheet (Unaudited) As at November 30, 2012 and November 30, 2011 2012 2011 Assets (notes 8 and 9) Current assets Cash and cash equivalents $ 4,539,160 $ 5,203,241 Accounts receivable (note 2) 5,974,873 3,703,749 Income taxes receivable 716,771 4,007 Inventory (note 3) 10,924,856 7,339,652 Prepaid expenses 334, |
|
| April 3, 2013 |
EXHIBIT INDEX Exhibit Number Description 23.1 Consent of ArsenaultBestCameronEllis, Independent Public Accounting Firm 99.1 BioVectra's audited consolidated financial statements for the fiscal year ended August 31, 2012 and 2011 99.2 BioVectra's unaudited condensed consolidated interim financial statements for the three month periods ended November 30, 2012 and 2011 99.3 Unaudited pro forma combin |
|
| April 3, 2013 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION EX-99.3 6 exhibit993proformafinancia.htm EXHIBIT Exhibit 99.3 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION The accompanying unaudited pro forma combined financial statements present the pro forma consolidated financial position and results of operations of the combined company based upon the historical financial statements of Questcor Pharmaceuticals, Inc. ("Questcor") and BioVectra Inc. ("B |
|
| April 3, 2013 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K/A 1 a8-kaproforma.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juri |
|
| April 3, 2013 |
Consent of Independent Public Accounting Firm Exhibit 23.1 Consent of Independent Public Accounting Firm We consent to the inclusion in this Current Report on Form 8-K/A of our report dated November 2, 2012, except as to Note 17 which is as of February 25, 2013, of our audits of the consolidated financial statements of BioVectra Inc. as of August 31, 2012, August 31, 2011 and September 1, 2010 and for the years ended August 31, 2012 and Augus |
|
| March 4, 2013 |
EX-99.2 3 d495264dex992.htm EX-99.2 Exhibit 99.2 QUESTCOR PHARMACEUTICALS FOURTH QUARTER 2012 FINANCIAL RESULTS February 26, 2013, 4:30 PM ET • MANAGEMENT DISCUSSION SECTION Operator: Good day, ladies and gentlemen, and welcome to the Questcor Pharmaceutical’s Fourth Quarter 2012 Earnings Conference. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-an |
|
| March 4, 2013 |
NASDAQ: QCOR Fourth Quarter and Full Year 2012 Conference Call EX-99.3 4 d495264dex993.htm EX-99.3 Exhibit 99.3 NASDAQ: QCOR Fourth Quarter and Full Year 2012 Conference Call Conference Call Logistics Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 95427085 By webcast: At Q |
|
| March 4, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Com |
|
| March 4, 2013 |
EX-99.1 2 d495264dex991.htm EX-99.1 Exhibit 99.1 Questcor Reports Fourth Quarter and Full Year 2012 Results - Net Sales, EPS and Cash Flow from Operations Increase Significantly Over Prior Year Period – - Continues to Expand R&D Efforts - - Increases Quarterly Dividend 25% to $0.25 per share - ANAHEIM, Calif., February 26, 2012 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financi |
|
| February 14, 2013 |
QCOR / / Flynn James E Passive Investment SC 13G/A 1 e610555sc13g-questcor.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Questcor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74835Y101 (CUSIP Number) D |
|
| February 11, 2013 |
QCOR / / VANGUARD GROUP INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Questcor Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 74835Y101 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| January 18, 2013 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 d467354d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisd |
|
| January 9, 2013 |
EX-99.1 2 d464037dex991.htm QUESTCOR PHARMACEUTICALS, INC. INVESTOR PRESENTATION January 2013 January 2013 NASDAQ: QCOR NASDAQ: QCOR JP Morgan 2013 Healthcare Conference Steve Cartt Chief Operating Officer Exhibit 99.1 1 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Priv |
|
| January 9, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d464037d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdi |
|
| January 4, 2013 |
Joint Press Release Exhibit 99.1 Questcor Pharmaceuticals to Acquire BioVectra Inc. — Transaction provides vertical integration, third party manufacturing capabilities and further secures Acthar manufacturing trade secrets — — Acquisition expected to be accretive to future financial results — ANAHEIM, Calif., January 2, 2013 — Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) today announced that it ha |
|
| January 4, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 d458579d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2013 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdi |
|
| October 25, 2012 |
EX-99.3 4 d429669dex993.htm PRESENTATION SLIDES 1 1 Third Quarter 2012 Conference Call Third Quarter 2012 Conference Call NASDAQ: QCOR Exhibit 99.3 2 • Today’s webcast, accompanying slide presentation and archived replay is available online at • Telephone replay is available by dialing: – U.S.: (855) 859-2056. – International: (404) 537-3406. – Passcode: 39696380 • By webcast: At Questcor's invest |
|
| October 25, 2012 |
EX-99.2 3 d429669dex992.htm TRANSCRIPT OF CONFERENCE CALL Exhibit 99.2 QUESTCOR PHARMACEUTICALS THIRD QUARTER 2012 FINANCIAL RESULTS October 23, 2012, 4:30 PM ET MANAGEMENT DISCUSSION SECTION Operator: Good day, ladies and gentlemen, and welcome to your Questcor Pharmaceutical’s Q3 2012 Earnings Conference. [Operator Instructions] But later, we will conduct a question-and-answer session, which ins |
|
| October 25, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d429669d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 23, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisd |
|
| October 25, 2012 |
Questcor Reports Third Quarter Financial Results EX-99.1 2 d429669dex991.htm PRESS RELEASE Exhibit 99.1 Questcor Reports Third Quarter Financial Results ANAHEIM, Calif., October 23, 2012 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the third quarter and nine months ended September 30, 2012. Three Months Ended 9/30/12 Three Months Ended 9/30/11 Percentage Change Net Sales $ 140.3 Million $ 59.8 Million 135 |
|
| October 15, 2012 |
QCOR / / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| October 9, 2012 |
Regulation FD Disclosure, Results of Operations and Financial Condition 8-K 1 d421734d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdi |
|
| September 28, 2012 |
Questcor Pharmaceuticals Initiates Quarterly Cash Dividend and Expands Stock Repurchase Program EX-99.1 2 d418510dex991.htm PRESS RELEASE Exhibit 99.1 Questcor Pharmaceuticals Initiates Quarterly Cash Dividend and Expands Stock Repurchase Program ANAHEIM, Calif., September 28, 2012 - Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) today announced that its Board of Directors has adopted a policy to pay a regular quarterly dividend in such amounts as the Board of Directors may determine from time |
|
| September 28, 2012 |
8-K 1 d418510d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juri |
|
| September 24, 2012 |
Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 19, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d413961d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juri |
|
| September 19, 2012 |
Questcor Comments on Insurance Policy Bulletin Questcor Pharmaceuticals, Inc. Press Release dated September 19, 2012. Exhibit 99.1 Questcor Comments on Insurance Policy Bulletin ANAHEIM, Calif., September 19, 2012 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today commented on information regarding an insurance policy bulletin issued with respect to the Company’s primary product H.P. Acthar® Gel (repository corticotropin injection) (“Acthar |
|
| September 10, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 10, 2012 |
EX-99.1 2 d408918dex991.htm INVESTOR PRESENTATION 1 September 2012 September 2012 1 Exhibit 99.1 NASDAQ: QCOR 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financia |
|
| September 7, 2012 |
8-K 1 d405794d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juris |
|
| September 5, 2012 |
- CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 ATTENTION: Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker. 1(a) NAME OF ISSUER (b) IRS IDENT. NO. (c) S.E.C. FI |
|
| September 4, 2012 |
8-K 1 d405580d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juris |
|
| August 17, 2012 |
CORRESP 1 filename1.htm Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 August 17, 2012 VIA EDGAR CORRESPONDENCE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended D |
|
| August 14, 2012 |
8-K 1 d395325d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdi |
|
| August 14, 2012 |
EX-99.1 2 d395325dex991.htm CEASE AND DESIST LETTER Exhibit 99.1 JOHN F. CANNON (949) 725-4107 [email protected] STRADLING YOCCA CARLSON & RAUTH, P.C. 660 NEWPORT CENTER DRIVE, SUITE 1600 NEWPORT BEACH, CA 92660-6422 SYCR.COM NEWPORT BEACH 949.725.4000 SACRAMENTO 916.449.2350 SAN DIEGO 858.926.3000 SAN FRANCISCO 415.283.2240 SANTA BARBARA 805.730.6800 SANTA MONICA 424.214.7000 August 13, 2012 VIA C |
|
| August 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 31, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d387415d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| July 31, 2012 |
EX-99.1 2 d387415dex991.htm PRESENTATION MADE BY QUESTCOR PHARMACEUTICALS, INC. 1 1 July 31, 2012 NASDAQ: QCOR NASDAQ: QCOR Exhibit 99.1 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future ev |
|
| July 30, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d385342d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| July 30, 2012 |
EX-99.1 2 d385342dex991.htm QUESTCOR PHARMACEUTICALS, INC. PRESS RELEASE Exhibit 99.1 Questcor Reports Second Quarter Financial Results -Net Sales and EPS More Than Double from Year Ago Quarter- -Sales Force Expansions Nearly Complete—Rheumatology Pilot Underway- -Conference Call and Webcast Today at 4:30 p.m. ET, 1:30 p.m. PT- ANAHEIM, Calif., July 24, 2012 — Questcor Pharmaceuticals, Inc. (NASDA |
|
| July 30, 2012 |
EX-99.2 3 d385342dex992.htm TRANSCRIPT OF CONFERENCE CALL Exhibit 99.2 QUESTCOR PHARMACEUTICALS SECOND QUARTER 2012 FINANCIAL RESULTS July 24, 2012, 4:30 PM ET MANAGEMENT DISCUSSION Operator: Ladies and gentlemen, thank you for standing by and welcome to the Questcor Pharmaceuticals Second Quarter 2012 Financial Results Conference Call. During today’s presentation, all participants will be in a li |
|
| July 30, 2012 |
EX-99.3 4 d385342dex993.htm PRESENTATION SLIDES USED DURING CONFERENCE CALL 1 Second Quarter 2012 Conference Call Second Quarter 2012 Conference Call NASDAQ: QCOR NASDAQ: QCOR 1 Exhibit 99.3 • Today’s webcast, accompanying slide presentation and archived replay are available online at • Telephone replay is available by dialing: – U.S.: 877-941-9205 – International: 480-629-9819 • Replay Passcode: |
|
| July 16, 2012 |
Questcor Pharmaceuticals, Inc. 1300 North Kellogg Drive, Suite D Anaheim, California 92807 July 16, 2012 VIA EDGAR CORRESPONDENCE Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: Questcor Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2011 Filed Feb |
|
| July 13, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 13, 2012 |
Questcor Pharmaceuticals, Inc. Investor Presentation NASDAQ: QCOR July 13, 2012 JMP Securities Healthcare Conference NASDAQ: NASDAQ: QCOR QCOR July 13, 2012 July 13, 2012 JMP Securities Healthcare Conference JMP Securities Healthcare Conference Exhibit 99.1 1 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements |
|
| July 9, 2012 |
Regulation FD Disclosure, Results of Operations and Financial Condition 8-K 1 d378710d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| June 19, 2012 |
Press Release Exhibit 99.1 Questcor Announces Initial Commercialization Plans for Acthar Rheumatology Indications - Peer-Reviewed Paper Published Earlier This Week on the Clinical Use of Acthar in the Treatment of Polymyositis and Dermatomyositis- -Conference Call and Webcast Today at 4:30 p.m. ET, 1:30 p.m. PT- ANAHEIM, Calif., June 14, 2012 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today a |
|
| June 19, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d367854d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| June 19, 2012 |
EX-99.2 3 d367854dex992.htm PRESENTATION SLIDES 1 1 1 NASDAQ: QCOR NASDAQ: QCOR June 14, 2012 Investor Update – Rheumatology June 14, 2012 Investor Update – Rheumatology Exhibit 99.2 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act |
|
| June 19, 2012 |
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR Rheumatology Commercialization Update Call) EX-99.3 4 d367854dex993.htm TRANSCRIPT OF CONFERENCE CALL Exhibit 99.3 Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR Rheumatology Commercialization Update Call) June 14, 2012 MANAGEMENT DISCUSSION Operator: Good day, ladies and gentlemen, thank you for standing by. Welcome to Questcor Rheumatology Commercial Plan Conference Call. During today’s presentation, all parties will be in a listen-only mod |
|
| June 6, 2012 |
EX-99.1 2 d360089dex991.htm QUESTCOR PHARMACEUTICALS, INC. INVESTOR PRESENTATION June 6, 2012 Jeffries NASDAQ: QCOR NASDAQ: QCOR Exhibit 99.1 1 2 Safe Harbor Statement 2 Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to |
|
| June 6, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d360089d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| May 22, 2012 |
QCOR / / BROADWOOD PARTNERS, L.P. Activist Investment SC 13D/A 1 d129324413d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2*) Questcor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74835Y101 (CUSIP Number) Neal C. Bradsher c/o Broadwood Capital, Inc. 724 Fifth Avenue, 9th Floor New York, New York 10019 (Name, Address a |
|
| May 21, 2012 |
QCOR / / BROADWOOD PARTNERS, L.P. Activist Investment SC 13D/A 1 d129307713d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) Questcor Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 74835Y101 (CUSIP Number) Neal C. Bradsher c/o Broadwood Capital, Inc. 724 Fifth Avenue, 9th Floor New York, New York 10019 (Name, Address an |
|
| May 16, 2012 |
Questcor Pharmaceuticals Expands Repurchase Program Press Release Exhibit 99.1 Questcor Pharmaceuticals Expands Repurchase Program ANAHEIM, Calif., May 16, 2012 /PRNewswire/ — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that its Board of Directors has increased the Company’s common share repurchase program authorization by an additional 5 million shares. Since the beginning of 2008, the Company has returned $236 million to shareho |
|
| May 16, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 16, 2012 |
EX-99.2 3 d353534dex992.htm PRESENTATION 1 May 16, 2012 Bank of America May 16, 2012 Bank of America NASDAQ: QCOR Exhibit 99.2 1 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or |
|
| May 16, 2012 |
Submission of Matters to a Vote of Security Holders 8-K 1 d354409d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdicti |
|
| May 8, 2012 |
8-K 1 d348541d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdictio |
|
| April 26, 2012 |
EX-99.1 2 d340254dex991.htm PRESS RELEASE Exhibit 99.1 Questcor Reports First Quarter 2012 Financial Results -Net Sales Grew to $96.0M vs. $36.8M in Q1 2011- -GAAP Net Income per Diluted Share Grew to $0.58 vs. $0.17 in Year Ago Period- -Value of First Quarter paid NS Prescriptions Exceeds MS Value- -Expansion of Both NS and MS Sales Forces Well Ahead of Schedule- -Conference Call and Webcast Toda |
|
| April 26, 2012 |
Questcor Pharmaceuticals (Nasdaq: QCOR Q1 2012 Earnings Call) Transcript of Conference Exhibit 99.2 Questcor Pharmaceuticals (Nasdaq: QCOR Q1 2012 Earnings Call) April 24, 2012 MANAGEMENT DISCUSSION Operator: Good day, ladies and gentlemen and welcome to the Questcor Pharmaceuticals, Inc. Q1 2012 earnings call. As a reminder, today’s conference is being recorded for replay purposes. I would now like to turn the conference over to your host for today, Mr. Dou |
|
| April 26, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d340254d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2012 Date of Report (Date of earliest event reported): April 24, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or |
|
| April 26, 2012 |
EX-99.3 4 d340254dex993.htm PRESENTATION SLIDES USED DURING CONFERENCE CALL First Quarter 2012 Conference Call First Quarter 2012 Conference Call NASDAQ: QCOR NASDAQ: QCOR Exhibit 99.3 1 2 • Today’s webcast, accompanying slide presentation and archived replay is available online at http://ir.questcor.com/events.cfm • Telephone replay is available by dialing: – U.S.: 855-859-2056 – International: 4 |
|
| April 9, 2012 |
Regulation FD Disclosure, Results of Operations and Financial Condition 8-K 1 d330880d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 9, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| March 30, 2012 |
- QUESTCOR PHARMACEUTICALS, INC. DEFA14A DEFA14A 1 d321514ddefa14a.htm QUESTCOR PHARMACEUTICALS, INC. DEFA14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| March 30, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d321526ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Def |
|
| March 12, 2012 |
Presentation made by Questcor Pharmaceuticals, Inc. 1 1 Exhibit 99.1 2 Safe Harbor Statement 2 Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can i |
|
| March 12, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 9, 2012 |
8-K 1 d313007d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdict |
|
| February 27, 2012 |
Presentation Slides 1 1 Fourth Quarter 2011 Conference Call Fourth Quarter 2011 Conference Call NASDAQ: QCOR NASDAQ: QCOR Exhibit 99. |
|
| February 27, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2012 Date of Report (Date of earliest event reported): February 22, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdiction of I |
|
| February 27, 2012 |
EX-99.1 2 d306778dex991.htm PRESENTATION MADE BY QUESTCOR PHARMACEUTICALS, INC. 1 1 NASDAQ: QCOR NASDAQ: QCOR Exhibit 99.1 February 27, 2012 Citigroup 2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relat |
|
| February 27, 2012 |
Press Release Exhibit 99.1 Questcor Reports Fourth Quarter and Full Year 2011 Financial Results -Q4 2011 Net Sales of $75.5M vs. $29.3M in Q4 2010- -Q4 2011 Net Income per Diluted Share of $0.48 vs. $0.10 in Q4 2010- -2011 Net Sales of $218.2 Million vs. $115.1M in 2010- -2011 Net Income per Diluted Share of $1.21 vs. $0.54 in 2010- -Conference Call and Webcast to Be Held Today at 4:30 p.m. ET, 1: |
|
| February 27, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d306778d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juris |
|
| February 27, 2012 |
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) Q4 and 2011 Earnings Call February 22, 2012 Transcript of Conference Call Exhibit 99.2 Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) Q4 and 2011 Earnings Call February 22, 2012 MANAGEMENT DISCUSSION Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Questcor Fourth Quarter and Fiscal Year 2011 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the pres |
|
| February 16, 2012 |
Questcor Pharmaceuticals, Inc. Investor Presentation 1 1 February 16, 2012 Leerink Swann NASDAQ: QCOR NASDAQ: QCOR Exhibit 99.1 2 Safe Harbor Statement Except for the historical information contained herein, this presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that c |
|
| February 16, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 d301934d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Juris |
|
| February 10, 2012 |
QCOR / / VANGUARD GROUP INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.:0 )* Name of issuer: Questcor Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 74835Y101 Date of Event Which Requires Filing of this Statement: December 31, 2011 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 3, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d294233d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisd |
|
| February 3, 2012 |
Questcor Announces Preliminary Fourth Quarter and Full Year 2011 Net Sales and Operating Income Press Release Exhibit 99.1 Questcor Announces Preliminary Fourth Quarter and Full Year 2011 Net Sales and Operating Income ANAHEIM, CA – February 3, 2012 — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it expects to report net sales of approximately $75 million and operating income of approximately $41 million to $43 million for the quarter ended December 31, 2011, as compared |
|
| January 9, 2012 |
EX-99.1 2 d278517dex991.htm QUESTCOR PHARMACEUTICALS, INC. PRESS RELEASE DATED JANUARY 6, 2012 Exhibit 99.1 QUESTCOR PHARMACEUTICALS REPORTS STRONG FINISH TO 2011 Paid Acthar Prescriptions for MS Up Approximately 165% Year-Over-Year Compared to Fourth Quarter 2010 Paid Acthar Prescriptions for Nephrotic Syndrome Up Approximately 145% Sequentially Compared to Third Quarter 2011 Further Expansion of |
|
| January 9, 2012 |
8-K 1 d278517d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2012 QUESTCOR PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) California 001-14758 33-0476164 (State or Other Jurisdi |
|
| January 9, 2012 |
EX-99.2 3 d278517dex992.htm PRESENTATION MADE BY QUESTCOR PHARMACEUTICALS, INC. 1 1 January 2012 JP Morgan Healthcare Conference January 2012 JP Morgan Healthcare Conference Exhibit 99.2 2 Safe Harbor Statement Except for the historical information contained herein, this presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject |
